Skip to main content
. 2013 Aug 5;18(8):947–953. doi: 10.1634/theoncologist.2013-0096

Figure 1.

Figure 1.

Approximate incidence of common mutations in adenocarcinoma. Numbers should be considered approximate to illustrate the relative frequency of these changes as they have never been all reported in the same series and estimates vary. References: EGFR [11, 12], Kirsten rat sarcoma viral oncogene homolog (kRAS) [12], echinoderm microtubule-associated protein-like 4/anaplastic lymphoma kinase (EML4/ALK) [13], ROS1 [14, 15], BRAF [12], Phosphatidylinositol-4,5-Bisphosphate 3-Kinase (PIK3CA) [12], hepatocyte growth factor receptor (MET) [12] (note: this rate refers to MET mutation; overexpression is more common), Human Epidermal Growth Factor Receptor 2 (HER2) [12], Other/unknown [12].